Saint Luke's Cancer Institute joins with Garmin, TeraCrunch for wearable study

Listen
Text
  • Small
  • Medium
  • Large

Saint Luke's Cancer Institute in Kansas City, Mo., has partnered with Olathe, Kan.-based wearable tech company Garmin and Overland Park, Kan.-based data analytics firm TeraCrunch to launch a study of advanced cancer patients.

The study will begin in mid-June, when 50 to 70 stage four cancer patients at Saint Luke's will receive Garmin Viviosmart 4 wearable devices. As the devices track factors such as the patients' heart rates, sleep patterns and stress levels, TeraCrunch will use that data to develop artificial intelligence algorithms that can predict when patients will experience adverse reactions and when a physician must be notified.

"When you have advanced cancer and you're undergoing treatment, there are side effects from the treatment and side effects and complications from the cancer itself," Tim Pluard, MD, Saint Luke's medical director, said. "Every time you have one of these events, you're draining your reserves, and these patients have limited reserves."

More articles about health IT:
Most oncologists expect AI to improve patient outcomes in coming years, report finds: 3 notes
Physician viewpoint: The Apple Watch is helpful, but not a medical device
IBM Watson Health's clinical support in cancer care proven by multiple studies

Copyright © 2021 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars